Fundraise

CytoSorbents raises $4M to cut debt and extend its 2028 runway

What's the deal? CytoSorbents, a Princeton-based maker of blood purification technology for intensive care and cardiac surgery, raised $4 million in a registered direct offering of common stock. Avenue Venture Opportunities Fund participated, and roughly 75% of the round was subscribed by existing shareholders and the company's management and board.

The terms: The Nasdaq-listed company (NASDAQ: CTSO) sold shares at $4.94 each, plus pre-funded warrants, pricing the deal at-the-market under Nasdaq rules. H.C. Wainwright & Co.Dealroom has a profile for this one. Try Dealroom → acted as exclusive placement agent; WBB Securities served as financial advisor.

What's the money for? CytoSorbents will use net proceeds to repay $3 million in principal under its loan agreement with Avenue Capital GroupDealroom has a profile for this one. Try Dealroom →, along with a $52,500 prepayment fee and a $270,000 final payment. The rest goes to general corporate and working capital purposes.

Why now? The financing ran alongside a restructuring of the company's Avenue credit facility. Together, the moves cut total debt by $5.25 million to $12.25 million and are expected to save about $0.7 million in interest over 12 months.

What's the endgame? The amended loan pushes maturity out one year to July 1, 2028, and extends the interest-only period by 15 months through March 31, 2028. That buys CytoSorbents more runway with lower near-term cash obligations.

The signal: For a small-cap medtech firm, a modest raise backed heavily by insiders and paired with a debt restructuring points to a balance-sheet cleanup rather than growth capital — a familiar playbook for companies managing lender relationships while preserving cash.

Read more: centralcharts.com

Image credit: "Cardiac operating room" by Ruhrfisch, licensed under CC BY-SA 2.0

More top stories